Eli Lilly halts development of Alzheimer's drug
Tuesday, August 17, 2010 at 01:01PM By TOM MURPHY
INDIANAPOLIS – Eli Lilly and Co. has stopped developing a potentialAlzheimer's disease treatment at a time when the drugmaker is searching wide and far for new drugs to fill a large revenue hole that will form starting next year.
The Indianapolis company said Tuesday preliminary results from late-stage studies of semagacestat showed it did not slow the progression of Alzheimer's, and patients taking the drug actually fared worse than those on a placebo.
Despite the setback, Lilly Chairman and CEO John Lechleiter said the company remains committed to developing new drugs while competitors make large-scale acquisitions. The industry is racing to compensate for patent expirations that will hit in the next few years and expose many key drugs to generic competition.
"In a risky business like ours, these things do happen," he said. "One failure of this sort does not undermine our strategy."
Lilly has eight drugs in late-stage testing, the last step before a company seeks regulatory approval. That includes potential cancer and diabetes treatments and another Alzheimer's drug. The company also touts a pipeline of nearly 70 that are in some form of human testing.
It also is awaiting a Food and Drug Administration decision on its antidepressant Cymbalta as a possible chronic pain treatment and a longer-acting version of Byetta, a diabetes drug on which it partners with Amylin Pharmaceuticals.
Lilly, which supplements its pipeline with several smaller-scale acquisitions, faces one of the worst "patent cliffs" in the industry. It loses protection for its top seller, the anti-psychotic Zyprexa, next year and its second-best seller, Cymbalta, in 2013.
In addition, a U.S. District Court judge has ruled invalid a patent protecting the attention deficit hyperactivity drug Strattera. Lilly expects generic competition to enter the market soon.
To counter all this, Lilly aims to launch two new drugs a year by 2013.
"We think we're plenty big enough to continue to innovate and to bring new medicines forward that will help Lilly resume a growth trajectory following the expiration of these various patents," Lechleiter said.
However, analysts covering the company have doubts. Bernstein analyst Dr. Tim Anderson said in a research note Lilly's lineup of drugs in late-stage development "looks relatively thin."
"The company has disavowed doing bigger deals which implies it is counting on its pipeline to deliver," Anderson wrote. "Today's setback would seem to make this more difficult to achieve."
Lilly said Tuesday patients taking semagacestat saw their cognition, or memory and reasoning skills, and their ability to complete daily living activities like getting dressed worsen "to a statistically significantly greater degree" than patients taking a placebo.
The drug also was tied to an increased risk of skin cancer. Lilly said the decision to halt semagacestat's development will not affect its other potential Alzheimer's treatment, solanezumab.
There is no known cure for Alzheimer's disease. Drugs on the market that treat it only temporarily alleviate symptoms. Scientists aren't even sure what causes Alzheimer's.
Earlier this year, Pfizer Inc. and partner Medivation Inc. said the promising Alzheimer's treatment Dimebon failed to work in a late-stage study, but the companies are continuing another study of the drug as an add-on treatment for Alzheimer's.
Johnson & Johnson also is developing the potential treatment bapineuzumab, and several other Alzheimer's treatments are in late-stage testing.
Shares of Lilly slipped 2.6 percent to $34.66 in midday trading Tuesday.
From Yahoo News
IMPORTANT: No advice is offered or given in this article or this publication. PLEASE ALWAYS REFER TO AN EXPERT before acting on any information contained in any of our stories.
Copyright © 2006-10, Blogertize Publications (http://www.blogertize.com), except as otherwise indicated. Text may be excerpted UNALTERED with FULL CREDIT and LINK. PHOTOS MAY NOT BE COPIED, DOWNLOADED OR REPRODUCED WITHOUT PERMISSION. Note: Some photos of real people may be models used to illustrate the editorial concept. MISSION: "You Need to Know" Our publications are daily online newspapers and magazines (webzines), plus delivered Ezines. Our stories also appear on various newswire services and are picked up in other publications. Our reporters and journalists break or report stories and their sources and source information are protected by the doctrine of free press as expressed in the First Amendment, Reporter's Privilege statutes, and also the Canadian Charter of Rights and Freedoms. COMMENTS FROM USERS: We invite dialogue and comments from our readers and limit moderation to obscenity and privacy issues, however WE ACCEPT NO RESPONSIBILITY WHATSOEVER FOR THIS CONTENT. We believe in the doctrine of FREE SPEECH. COMMENTS AND MOST STORIES ARE FROM OUTSIDE CONTRIBUTORS AND READERS AND NOT A REFLECTION OF THE OPINIONS OF THIS MAGAZINE. The opinions expressed by our writers, columnists and reporters are their opinions and do not necessarily reflect the opinion of this magazine, its writers and staff, or Blogertize Publications.TM - Our magazine names are trademarked. Our publications team provide this ezine and web site and its contents in good faith but makes no representations or warranties of any kind with respect to this web site or its contents. We disclaim any representations and warranties, whether express or implied, including, but not limited to warranties of any kind. In addition, we do not represent or warrant that the information accessible via this web site or the products or services sold or given free on it are accurate, complete or current. Errors and Omissions Excepted. By using/visiting this site you agree that use information herein is at your own risk. PRIVACY: SPAM POLICY: We do not use, nor do we condone the use of unsolicited bulk email. Our email system is an opt-in only. Please report any incidents of unsolicited email coming from or mentioning our domain to editor AT blogeritze.com. All matters will be investigated and dealt with promptly. Jurisdiction: Any action or dispute arising from the use of information on this site will be deemed to have been undertaken and concluded in Toronto, Canada and will be interpreted, construed and enforced in all respects in accordance with the laws of Canada and all parties thereto shall submit to the exclusive jurisdiction of the Ontario courts. A visitor agrees that the applicable law to be applied shall, in all cases, be that of the city of the web site owner, namely, Toronto, Canada.
Persona Corp. and Blogertize publishes several webzines, magazines, e-zines for news, entertainment and information, but cautions readers to read the USAGE NOTICE. Our mandate: "You Need to Know!"
• Auto News (autonews.co): The latest news, reviews and views on all things automobile
• Automobile Buzz (automobilebuzz.com): Everyone's favorite zine with the latest road tests, videos, and breaking news with special focus on sportscars and greencars
• Films and Books Magazine - News from Hollywood and New York, Books and Films
• Webzine (webzine.co): Reviews of the best, newest and brightest of webzines, print to web conversion zines, ezines and online publications.
* Noetic News: News, Features, Research on the Science of Consciousness
* Dog and Cat World: You can't know too much about your best friend.
* Advance Magazine - Body, Mind, Spirit
* LINK Magazine: Good News Report
* Buddha Weekly - Buddhist news, events, profiles from all traditions.
Social Network
Contributors
• Derek Armstrong, Chief Crime Correspondent, Crime Report USA, contributor various
Reader Comments